Immuno-oncology company Nouscom, a developer of off-the-shelf and personalised neoantigen-based genetic cancer vaccines based on its proprietary technology platform, revealed on Monday that John F McDonald has been appointed to its board of directors, as an independent director.
With over 25 years experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries, McDonald has expertise that involves academic institutions and biotech and pharmaceutical companies of all stages, including financing, acquisitions, R&D collaborations and in-licensing agreements, among others, the company stated.
McDonald is currently Corporate VP, Global Business Development at Novo Nordisk.
Previously, he served as VP Business Development at Biogen Inc, managing director at healthcare investment firm MPM Capital and VP Business Development at Millennium Pharmaceuticals.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business